Becker's Healthcare July 8, 2024
Paige Twenter

Eli Lilly will acquire Morphic, a Massachusetts-based biopharmaceutical company, for about $3.2 billion by the end of 2024.

Morphic’s lead product is an oral small molecule inhibitor that is a potential inflammatory bowel disease treatment, according to a July 8...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
How Americans feel about weight-loss drugs, in 3 charts
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science
Healthcare supply chain, pharmacy costs to rise in 2025: report

Share This Article